Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Henry Schein (HSIC) announced a strategic investment by funds affiliated with KKR,(KKR) a global investment firm.In addition to KKR’s current ...

Henry Schein announced today that private equity firm KKR is investing $250 million in the medical products manufacturer and ...

Henry Schein, Inc., has announced that Stanley M. Bergman, chairman of the board and CEO, has received the National Association of Wholesaler-Distributors (NAW) Dirk Van Dongen Lifetime ...

Henry Schein (NASDAQ:HSIC – Free Report) had its price objective hoisted by Barrington Research from $82.00 to $90.00 in a research note published on Thursday,Benzinga reports. They currently ...

Read Our Latest Stock Analysis on Henry Schein Henry Schein Price Performance HSIC stock opened at $80.03 on Friday. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63 ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Henry Schein HSIC in the last three months. The table below offers a condensed view of their ...

Private equity firm KKR has taken a large stake in Henry Schein and reached a deal to add members to the company's board, the ...

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of ...